Sanders takes aim at US drug prices of Novo’s Ozempic and Wegovy
Pharmaceutical Technology
APRIL 25, 2024
A Senate Committee is investigating the “outrageously high” US price tags of the blockbuster diabetes and obesity drugs.
Pharmaceutical Technology
APRIL 25, 2024
A Senate Committee is investigating the “outrageously high” US price tags of the blockbuster diabetes and obesity drugs.
Pharmaceutical Technology
JANUARY 17, 2023
Bimagrumab is of interest in the obesity space as it is a first-in-class therapy for obesity. Bimagrumab is an activin receptor type 2B (ACVR2B or EC 2.7.11.30) antagonist that offers a unique mechanism of action within the obesity market. Mounjaro is anticipated to launch in the US later this year or by early 2024.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
World of DTC Marketing
NOVEMBER 3, 2020
has also seen reversals in health improvements since 2010, partly due to increasing rates of obesity, high blood pressure, and high blood sugar. . Obesity, lack of exercise, and too much salt are all contributing to a myriad of health issues that are going to drive up healthcare costs. is lower than in other high-income countries.
Rethinking Clinical Trials
AUGUST 22, 2022
Core Faculty, Center for Pediatric Obesity Medicine. ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ?. Speakers. Carolyn Bramante, MD, MPH. Assistant Professor, General Internal Medicine and Pediatrics. Core Faculty, Program for Health Disparities Research. University of Minnesota Medical School. Thomas Murray, PhD. Assistant Professor of Biostatistics.
XTalks
NOVEMBER 3, 2022
Lilly is also looking to pitch Mounjaro as an obesity drug and directly take on Novo’s Wegovy. The company is currently conducting a study to demonstrate Mounjaro’s weight loss effects and secured an FDA Fast Track tag in the obesity indication.
XTalks
APRIL 29, 2022
Eli Lilly announced that its obesity drug tirzepatide has scored favorably in a late-stage clinical trial, with results showing that people who took the drug lost an average of 50 pounds, or 21 percent, of their body weight compared to placebo. Since 1975, obesity rates have almost tripled worldwide. percent and 22.5 percent and 22.5
Delveinsight
JULY 22, 2020
The hospital inventory is equipped with tagged sensors. The sedentary lifestyle over the past few years has given rise to many chronic diseases such as blood pressure, cardiovascular diseases, depression , diabetes , obesity and anxiety. Medical Equipment Tracking. IoT can also be utilised in equipment tracking and management.
Let's personalize your content